Immuno-Oncology | Specialty

Resistance to Antiangiogenic Therapy in Lung Cancer

November 11th 2016

Antiangiogenic Antibodies vs TKIs in NSCLC

November 11th 2016

Blocking VEGFR2 vs VEGFA or VEGFB in Lung Cancer

November 11th 2016

Sequencing Therapies in Advanced Lung Adenocarcinoma

November 11th 2016

Patient Selection for Ramucirumab in NSCLC

November 11th 2016

Mechanisms of Anti-angiogenic Therapy in Lung Cancer

November 11th 2016

Bevacizumab in Nonsquamous Lung Cancer

November 11th 2016

Targeting Angiogenesis in Non–Small Cell Lung Cancer

November 11th 2016

Dysregulated Angiogenesis in Lung Cancer

November 11th 2016

Dr. Patrick M. Forde on Next Steps After CheckMate-026 Study in NSCLC

November 11th 2016

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses the CheckMate-026 study, which demonstrated that first-line therapy with nivolumab failed to improve progression-free survival (PFS) in PD-L1–positive non-small cell lung cancer (NSCLC) compared with standard chemotherapy.

FDA Approves Nivolumab for Head and Neck Cancer

November 11th 2016

The FDA has approved nivolumab for patients with metastatic or recurrent squamous cell carcinoma of the head and neck following progression on platinum-based therapy.

Nivolumab Improves OS in Phase III Gastric Cancer Study

November 11th 2016

Treatment with nivolumab significantly extended overall survival compared with placebo for patients with unresectable, advanced, or recurrent gastric cancer who were refractory or intolerant to standard therapy.

Dr. Ferris on FDA Approval of Nivolumab in Patients With Head and Neck Cancer

November 11th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCN).

Immunotherapy Agents Landing in Myeloma Landscape

November 10th 2016

Using combination regimens in an effective manner will likely be a go-to method with immunotherapy in multiple myeloma, in an effort to induce durable responses in patients.

Dr. Markman on Immune Targeting in Ovarian Cancer

November 10th 2016

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the current status of immune targeting as potential treatment for patients with ovarian cancer.

SD-101, Pembrolizumab Combo Well-Tolerated in Early-Stage Melanoma

November 10th 2016

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities.

Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma

November 8th 2016

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma

November 8th 2016

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma

November 8th 2016

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

Dr. Ryan Sullivan on Treating BRAF-Mutant Patients With Melanoma

November 8th 2016

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.